Designing Antibiotic Cycling Strategies by Determining and Understanding Local Adaptive Landscapes

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Goulart, Christiane P ^a   Mahmudi, Mentar ^b   Crona, Kristina A ^a   Jacobs, Stephen D ^a   Kallmann, Marcelo ^b   Hall, Barry G ^c   Greene, Devin C ^a   Barlow, Miriam ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Merced   (United States)

^c Bellingham Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE TEM 1; CEFACLOR; CEFEPIME; CEFOTAXIME; CEFOTETAN; CEFOXITIN; CEFPODOXIME; CEFPROZIL; CEFTAZIDIME; CEFTIZOXIME; CEFTRIAXONE; CEFUROXIME; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; ESCHERICHIA COLI; GENE FREQUENCY; GENETIC CODE; GENETIC VARIABILITY; MUTATIONAL ANALYSIS; NONHUMAN; PHENOTYPE; SIGNAL TRANSDUCTION;

ANTI-BACTERIAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; MICROBIAL SENSITIVITY TESTS; MUTAGENESIS, SITE-DIRECTED;

EID: 84873901473     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056040     Document Type: Article

References (56)

1. Andersson DI, Hughes D, (2011) Persistence of antibiotic resistance in bacterial populations. FEMS microbiology reviews 35: 901-911.
2. Brown EM, Nathwani D, (2005) Antibiotic cycling or rotation: a systematic review of the evidence of efficacy. J Antimicrob Chemother 55: 6-9.
3. Bergstrom CT, Lo M, Lipsitch M, (2004) Ecological theory suggests that antimicrobial cycling will not reduce antimicrobial resistance in hospitals. Proc Natl Acad Sci U S A 101: 13285-13290.
4. Livermore DM (1996) Are all beta-lactams created equal? Scand J Infect Dis Suppl 101: 33-43.
5. Shahid M, Sobia F, Singh A, Malik A, Khan HM, et al. (2009) Beta-lactams and beta-lactamase-inhibitors in current- or potential-clinical practice: a comprehensive update. Critical reviews in microbiology 35: 81-108.
6. Livermore DM, (2005) Minimising antibiotic resistance. Lancet Infect Dis 5: 450-459.
7. Matagne A, Lamotte-Brasseur J, Frere JM, (1998) Catalytic properties of class A beta-lactamases: efficiency and diversity [published erratum appears in 1998 May 1;331(Pt 3): 975]. Biochem J 330: 581-598.
8. Mroczkowska JE, Barlow M (2008) Fitness tradeoffs in blaTEM evolution. Antimicrob Agents Chemother.
9. Medeiros AA, (1997) Evolution and dissemination of beta-lactamases accelerated by generations of beta-lactam antibiotics. Clinical Infectious Diseases 24: S19-45.
10. Perron GG, Lee AE, Wang Y, Huang WE, Barraclough TG, (2012) Bacterial recombination promotes the evolution of multi-drug-resistance in functionally diverse populations. Proceedings Biological sciences/The Royal Society 279: 1477-1484.
11. Beardmore RE, Pena-Miller R, (2010) Rotating antibiotics selects optimally against antibiotic resistance, in theory. Mathematical biosciences and engineering: MBE 7: 527-552.
12. Beardmore RE, Pena-Miller R, (2010) Antibiotic cycling versus mixing: the difficulty of using mathematical models to definitively quantify their relative merits. Mathematical biosciences and engineering: MBE 7: 923-933.
13. Kimura M, Ohta T, (1971) Protein polymorphsim as a phase of molecular evolution. Nature 229: 467-469.
14. Kimura M, Ohta T, (1969) The Average Number of Generations until Fixation of a Mutant Gene in a Finite Population. Genetics 61: 763-771.
15. Kimura M (1983) The neutral theory of molecular evolution. New York: Cambridge University Press.
16. Kimura M (1983) Neutral Theory. In: Nei M, Koehn R, editors. Evolution of genes and proteins. Sunderland, Mass: Sinauer Associates.
17. Kimura M, (1962) On the probability of fixation of mutant genes in a population. Genetics 47: 713-719.
18. Coenen S, Ferech M, Dvorakova K, Hendrickx E, Suetens C, et al. (2006) European Surveillance of Antimicrobial Consumption (ESAC): outpatient cephalosporin use in Europe. J Antimicrob Chemother 58: 413-417.
19. Ferech M, Coenen S, Dvorakova K, Hendrickx E, Suetens C, et al. (2006) European Surveillance of Antimicrobial Consumption (ESAC): outpatient penicillin use in Europe. J Antimicrob Chemother 58: 408-412.
20. Ferech M, Coenen S, Malhotra-Kumar S, Dvorakova K, Hendrickx E, et al. (2006) European Surveillance of Antimicrobial Consumption (ESAC): outpatient quinolone use in Europe. J Antimicrob Chemother 58: 423-427.
21. Ferech M, Coenen S, Malhotra-Kumar S, Dvorakova K, Hendrickx E, et al. (2006) European Surveillance of Antimicrobial Consumption (ESAC): outpatient antibiotic use in Europe. J Antimicrob Chemother 58: 401-407.
22. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003. Am J Infect Control 31: 481-498.
23. Fridkin SK, Steward CD, Edwards JR, Pryor ER, McGowan JE Jr, et al. (1999) Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals. Clin Infect Dis 29: 245-252.
24. Steward CD, Wallace D, Hubert SK, Lawton R, Fridkin SK, et al. (2000) Ability of laboratories to detect emerging antimicrobial resistance in nosocomial pathogens: a survey of project ICARE laboratories. Diagn Microbiol Infect Dis 38: 59-67.
25. Tenover FC, Raney PM, Williams PP, Rasheed JK, Biddle JW, et al. (2003) Evaluation of the NCCLS extended-spectrum beta-lactamase confirmation methods for Escherichia coli with isolates collected during Project ICARE. J Clin Microbiol 41: 3142-3146.
26. Mendes RE, Castanheira M, Garcia P, Guzman M, Toleman MA, et al. (2004) First isolation of bla(VIM-2) in Latin America: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother 48: 1433-1434.
27. Walsh TR, Toleman MA, Hryniewicz W, Bennett PM, Jones RN, (2003) Evolution of an integron carrying blaVIM-2 in Eastern Europe: report from the SENTRY Antimicrobial Surveillance Program. J Antimicrob Chemother 52: 116-119.
28. Bell JM, Turnidge JD, Gales AC, Pfaller MA, Jones RN, (2002) Prevalence of extended spectrum beta-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: regional results from SENTRY Antimicrobial Surveillance Program (1998-99). Diagn Microbiol Infect Dis 42: 193-198.
29. Bell JM, Turnidge JD, Jones RN, (2002) Antimicrobial resistance trends in community-acquired respiratory tract pathogens in the Western Pacific Region and South Africa: report from the SENTRY antimicrobial surveillance program, (1998-1999) including an in vitro evaluation of BMS284756. Int J Antimicrob Agents 19: 125-132.
30. Fedler KA, Biedenbach DJ, Jones RN, (2006) Assessment of pathogen frequency and resistance patterns among pediatric patient isolates: report from the 2004 SENTRY Antimicrobial Surveillance Program on 3 continents. Diagn Microbiol Infect Dis 56: 427-436.
31. Moet GJ, Jones RN, Biedenbach DJ, Stilwell MG, Fritsche TR, (2007) Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Diagn Microbiol Infect Dis 57: 7-13.
32. Bell JM, Chitsaz M, Turnidge JD, Barton M, Walters LJ, et al. (2007) Prevalence and significance of a negative extended-spectrum beta-lactamase (ESBL) confirmation test result after a positive ESBL screening test result for isolates of Escherichia coli and Klebsiella pneumoniae: results from the SENTRY Asia-Pacific Surveillance Program. J Clin Microbiol 45: 1478-1482.
33. Hartl DL, Dykhuizen DE, Dean AM, (1985) Limits of adaptation: the evolution of selective neutrality. Genetics 111: 655-674.
34. Dykhuizen DE, Dean AM, Hartl DL, (1987) Metabolic flux and fitness. Genetics 115: 25-31.
35. Dykhuizen DE, Dean AM, (2004) Evolution of specialists in an experimental microcosm. Genetics 167: 2015-2026.
36. Dykhuizen DE, Dean AM, (1994) Predicted fitness changes aloing an environmental gradient. Evol Ecol 8: 524-541.
37. Dean JL, Wang XG, Teller JK, Waugh ML, Britton KL, et al. (1994) The catalytic role of aspartate in the active site of glutamate dehydrogenase. Biochem J 301: 13-16.
38. Dean CR, Visalli MA, Projan SJ, Sum PE, Bradford PA, (2003) Efflux-Mediated Resistance to Tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1. Antimicrob Agents Chemother 47: 972-978.
39. Dean AM, Dykhuizen DE, Hartl DL, (1988) Fitness effects of amino acid replacememts in the beta-Galactosidase of Escherichia coli. MolBiolEvol 5: 469-485.
40. Dean AM, Dykhuizen DE, Hartl DL, (1986) Fitness as a function of beta-galactosidase activity in Escherichia coli. Genetical Research 48: 1-8.
41. Dean AM, (1995) A molecular investigation of genotype by environment interactions. Genetics 139: 19-33.
42. Dean AM, (1989) Selection and neutrality in lactose operons of Escherichia coli. Genetics 123: 441-454.
43. Crona K, Greene D, Barlow M, (2012) The peaks and geometry of fitness landscapes. Journal of theoretical biology 317C: 1-10.
44. Beerenwinkel N, Pachter L, Sturmfels B, Elena SF, Lenski RE, (2007) Analysis of epistatic interactions and fitness landscapes using a new geometric approach. BMC evolutionary biology 7: 60.
45. Carneiro M, Hartl DL, (2010) Colloquium papers: Adaptive landscapes and protein evolution. Proceedings of the National Academy of Sciences of the United States of America 107Suppl 1: 1747-1751.
46. Franke J, Klozer A, de Visser JA, Krug J, (2011) Evolutionary accessibility of mutational pathways. PLoS computational biology 7: e1002134.
47. de Visser JA, Park SC, Krug J, (2009) Exploring the effect of sex on empirical fitness landscapes. Am Nat 174Suppl 1: S15-30.
48. Sirot D, Recule C, Chaibi EB, Bret L, Croize J, et al. (1997) A complex mutant of TEM-1 beta-lactamase with mutations encountered in both IRT-4 and extended-spectrum TEM-15, produced by an Escherichia coli clinical isolate. Antimicrobial agents and chemotherapy 41: 1322-1325.
49. Baraniak A, Fiett J, Mrowka A, Walory J, Hryniewicz W, et al. (2005) Evolution of TEM-type extended-spectrum beta-lactamases in clinical Enterobacteriaceae strains in Poland. Antimicrob Agents Chemother 49: 1872-1880.
50. Barlow M, Hall BG, (2002) Predicting evolutionary potential: in vitro evolution accurately reproduces natural evolution of the tem beta-lactamase. Genetics 160: 823-832.
51. Gillespie JH, (1978) A general model to account for enzyme variation in natural populations. Theor Pop Biol 14: 1-45.
52. Weinreich DM, Delaney NF, Depristo MA, Hartl DL, (2006) Darwinian evolution can follow only very few mutational paths to fitter proteins. Science 312: 111-114.
53. Crona K, Greene D, Barlow M, (2013) The Peaks and Geometry of Fitness Landscapes. Journal of Theoretical Biology 317: 1-10.
54. Sarraf-Yazdi S, Sharpe M, Bennett KM, Dotson TL, Anderson DJ, et al. (2012) A 9-Year retrospective review of antibiotic cycling in a surgical intensive care unit. The Journal of surgical research 176: e73-78.
55. Mroczkowska JE, Barlow M, (2008) Recombination and selection can remove blaTEM alleles from bacterial populations. Antimicrobial agents and chemotherapy 52: 3408-3410.
56. Institute CaLS (2008) Performance Standards for Antimicrobial Susceptibility Testing.